William Soliman on the national risks of tariffs on patient medicines

Biotech Innovation in China: From Fast Follower to Emerging Leader

China is now contributing a rapidly growing share of global drug development, driven by faster clinical execution, dense biotech clusters, returning scientific talent, and rising cross-border deal activity.

The Consequences of War for Drug Development and Delivery

Written by William Soliman, learn about the ongoing conflicts between Ukraine and Russia, as well as Israel and Palestine, have sent ripples across various industries, including pharma. Read more on how medical science liaisons can help

Biosimilars Require Standardization of Knowledge in the Field

Pharmacy Times sat down with a panel of experts to discuss progress toward standardization of knowledge in the field of biosimilars, with panelists including William Soliman, PhD, founder and CEO of the Accreditation Council for Medical Affairs (ACMA); Jeff Baldetti, MBA, BCBBS, vice president of product and marketing at HealthPlan Data Solutions; and Fran Gregory, PharmD, vice president of emerging therapies and biosimilars at Cardinal Health.

The Crucial Role of Medical Affairs in Bridging the Educational Gap Among Healthcare Professionals in Biosimilars

Biosimilars represent an important therapeutic option in modern healthcare, offering cost-effective alternatives to complex biological drugs. The educational gap among healthcare professionals poses a challenge to their widespread adoption. Medical Affairs teams in the pharmaceutical industry are at the forefront of bridging this gap

The Crucial Role of Medical Affairs in Bridging the Educational Gap Among Healthcare Professionals in Biosimilars

Biosimilars represent an important therapeutic option in modern healthcare, offering cost-effective alternatives to complex biological drugs. The educational gap among healthcare professionals poses a challenge to their widespread adoption. Medical Affairs teams in the pharmaceutical industry are at the forefront of bridging this gap

The Crucial Role of Medical Affairs in Bridging the Educational Gap Among Healthcare Professionals in Biosimilars

Biosimilars represent an important therapeutic option in modern healthcare, offering cost-effective alternatives to complex biological drugs. The educational gap among healthcare professionals poses a challenge to their widespread adoption. Medical Affairs teams in the pharmaceutical industry are at the forefront of bridging this gap

Pharma, PBMs Blame Each Other Under Intense Scrutiny from Sanders' Health Committee

CEOs from Eli Lilly, Sanofi, and Novo Nordisk, along with executives from three pharmacy benefit managers (PBMs), appeared before the Senate Committee on Health, Education, Labor and Pension (HELP) to address insulin price reform. These companies control 90% of the global insulin market. The Inflation Reduction Act (IRA) has forced them to cap insulin copays at $35 per month and cap insulin expenses for seniors at $2,000 per year through Medicare. The high cost of insulin was attributed to both PBMs and pharmaceutical companies, with senators criticizing the lack of transparency in PBM operations. Dr. William Soliman, founder and CEO of the Accreditation Council for Medical Affairs, highlighted the need for PBM reform and Congressional action to achieve results. The urgency for revolutionary changes in the prescription drug system was emphasized.

After working at Merck during the Vioxx scandal, this former sales rep is on a mission to fix the system

William Soliman, CEO and founder of the Accreditation Council for Medical Affairs (ACMA), is working to establish competency standards and prevent conflicts between medical affairs departments and marketing in the pharmaceutical industry. ACMA certifies and accredits medical affairs and medical science liaisons, and Soliman aims to create uniform standards for the profession to avoid future pharmaceutical scandals. He emphasizes the importance of ethics and appropriate reporting structures within medical affairs, separating it from commercial influences...

Interview with William Soliman on Medical Science Liaisons

In this episode, Dr. Soliman, CEO of the Accreditation Council for Medical Affairs (ACMA), about his background, the influence of his father, and the role of the pharmaceutical industry. Growing up in Jersey City, Will was encouraged by his parents to pursue a career in STEM, leading him to major in biochemistry in college. He discusses the impact of 9/11 on immigration policies and scientific output, as well as his early career as a pharmaceutical sales rep before transitioning to a medical science liaison role.

ACMA partners with the Pharmaceutical Research & Manufacturers Association in the Gulf (PhRMAG) to streamline Prior Authorization Challenges in the UAE

The Accreditation Council for Medical Affairs (ACMA) and The Pharmaceutical Research and Manufacturers Association in the Gulf (PhRMAG) have partnered to establish an endowment aimed at enhancing the skills and credentials of healthcare professionals in the Middle East Gulf Region. This collaboration, initiated by Husam Al Majali of Merck and Jamie Phares of Janssen, will offer the globally accredited Prior Authorization Certified Specialist (PACS) credential to major healthcare systems in the area. PhRMAG, representing leading biopharmaceutical research companies in the Gulf, focuses on advancing medical research and patient care, while ACMA is renowned for setting industry standards and providing accredited certifications for both the pharmaceutical industry and healthcare providers.

Dr. William Soliman highlighted in Forbes on the racial inequality gap in healthcare

Oprah Winfrey is releasing a new documentary called the Color of Care which highlights racial equality gaps in healthcare especially highlighted during the Covid19 pandemic. See Dr Soliman quoted and featured in this article published by Forbes regarding the importance of the work we are doing at the Accreditation Council for Medical Affairs (ACMA) around the establishment of standards for MSL and Medical affairs professionals as they play a very important role in educating the healthcare provider community.

Moment of Xen Interview on iHeart Radio with Xen Sams

Check out our founder and CEO Dr. William Soliman / Accreditation Council for Medical Affairs (ACMA) this weekend on iHeart Radio's A Moment of Xen w/t Xen Sams in My Healthy Minutes segment sponsored by Revere Securities where he'll discuss the ongoing opioid crisis in America, how psychedelics and cannabis are potentially used to treat addictions, mental and neurological disorders, and the priceless education the Accreditation Council for Medical Affairs (ACMA) is providing the pharmaceutical industry.

Rebuild US Healthcare at Reuters 2022

During the Reuters Event, there will be an industry-focused conversation on key topics leading pharma in 2022. This event is held to provide content that is driven by experts in their fields: marketing, commercial, data & analytics, patient engagement, patient advocacy, medical affairs, market access, RWE and clinical. As a Gold Sponsor and media partner, the event will offer continuing medical education/continuing education (CME/CE) credits to attendees.

Discussing the Merck and J&J Merger

March 3, 2021

The ACMA frequently provides expertise about the pharmaceutical industry. In this video, Founder & CEO of the ACMA, Dr. William Soliman, speaks on Al Jazeera about the unprecedented cooperation within the pharmaceutical industry to expedite the development of the COVID-19 vaccine.

US Government Deal with Gilead Sciences

July 6, 2020

The ACMA's Founder & CEO Dr. William Soliman speaks on Al Jazeera to discuss the US Government's deal with Gilead Sciences to secure the COVID-19 vaccine. Is this a sign for things to come? Will patients in developing countries have adequate access to COVID-19 vaccines?

Discussing the $260MM Opioid Settlement

October 24, 2019

The ACMA's Founder & CEO Dr. William Soliman on Al Jazeera Newshour discusses how the $260 million opioid settlement is a wakeup call to Pharma companies. Dr. Soliman indicates that pharma companies need to overhaul their “old ways” of training and preparing employees, who are responsible for educating doctors and healthcare providers.